For the first time, researchers show that two powerful antiretroviral drugs can provide complete protection against HIV when delivered topically by a sustained release intravaginal ring (IVR) device. The combination of tenofovir disoproxil fumarate and emtricitabine delivered at independently controlled rates via the pod-IVR was successful at preventing SHIV162p3 infection for over four months.